top of page
The Sage Group is at JPM/BIO Partnering in San Francisco from 13-16 January, 2025! Please click here to setup a meeting!
See Latest News!
30 YEARS OF GLOBAL TRANSACTIONS FOR BIOSCIENCE COMPANIES
The Sage Group
About
Track Record
Locations
Added Value
Sage Clients
Testimonials
Services
M & A
Licensing
Sage China
Sage Japan
Sage India
Team
News
Downloads
Contact
More
Use tab to navigate through the menu items.
Sage Group News
Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody
Starrygene ( https://www.starrygene.com/ ) is a clinical stage biotechnology company based in China, focused on XMVA09, a novel...
Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)
Serpin Pharma (“Serpin”) is an anti-inflammatory/immunology company focused on developing its patented (CoM and use) SP-16 LRP1 agonist...
Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors
Our client, Starmab Biomed Inc (“Starmab” or the “Company”), is a US/China-based biotech company headquartered at Beijing Zhongguancun...
bottom of page
